Results 171 to 180 of about 35,267 (219)
Some of the next articles are maybe not open access.
Haemophilus influenzae type b conjugate vaccine
Journal of Pediatric Health Care, 1988Abstract Hib conjugate vaccine was developed with the ultimate goal of providing an effective vaccine for infants and younger children. The conjugate vaccine is as safe as Hib polysaccharide vaccine and significantly more immunogenic. Because antibody production after vaccination with conjugate vaccine in children 18 months of age or older is ...
J J, Campion, D T, Casto
openaire +2 more sources
Haemophilus influenzae Type b Conjugate Vaccines
1995In summary, all of the Hib conjugate vaccines are highly immunogenic and efficacious in children older than 12-15 months of age, and HbOC, PRP-OMPC, and PRP-T are highly immunogenic and demonstrated to be efficacious in infants as young as 2 months old.
P J, Kniskern, S, Marburg, R W, Ellis
openaire +2 more sources
Haemophilus influenzae b-vaccination: the urgency for timely vaccination
European Journal of Pediatrics, 1997In Germany the annual number of systemic Haemophilus influenzae cases in unvaccinated children aged 3-60 months has recently been exceeded by the number of cases in children vaccinated at least once with the PRP-D, HbOC or OMP vaccines, which until 1995 have almost exclusively been used for H. influenzae b (Hib) vaccination.
R, von Kries, O, Böhm, A, Windfuhr
openaire +2 more sources
[Haemophilus influenzae vaccines].
Bulletin de l'Academie nationale de medecine, 1994The haemophilus vaccines are made of the type b capsular polysaccharide of haemophilus influenzae, polyribosylribitol phosphate (PRP), which is responsive of pathogenic power. However the responsiveness of children to PRP vaccine was found to be very poor in infants.
openaire +1 more source
Haemophilus influenzae type b vaccination
The Lancet, 1997A, Melhus, A, Hemansson
openaire +3 more sources
Haemophilus b Polysaccharide Vaccine-Reply
JAMA: The Journal of the American Medical Association, 1989In Reply. — We congratulate Coles et al on the innovative use of discharge diagnosis data, and we agree with the conclusion that the polysaccharide Haemophilus vaccine provided protective efficacy in children aged 24 to 59 months. A randomized trial of the vaccine in Finland 1 as well as three postlicensure case-control studies 2-4 all demonstrated a ...
openaire +1 more source
Third Vaccine for Haemophilus influenzae?
JAMA: The Journal of the American Medical Association, 1991THE WAY has been opened to license a third vaccine againstHaemophilus influenzaefor use in 2-month-old infants. Pasteur Merieux, Swiftwater, Pa, the manufacturer of the third vaccine, was in the midst of two double-blind, placebo-controlled studies a year ago when the Food and Drug Administration (FDA) licensed a vaccine againstH influenzaeto Lederle ...
openaire +1 more source